Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, No. 8 (Apr. 15, 1987), pp. 2459-2463 (5 pages) The human C3b/C4b receptor (Cr1) is a Mr≈ 200,000 single-chain ...
In the alternative pathway, C3b binds to Factor B. Factor D releases Factor Ba from Factor B bound to C3b. The complex of C3b (2)Bb is a protease which cleaves C5 into C5b and C5a. C5 convertase is ...
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...
PHILADELPHIA - A team from the University of Pennsylvania School of Medicine and Utrecht University has deciphered a key step in an evolutionarily old branch of the immune response. This system, ...
Two functions have been assigned to properdin; stabilization of the alternative convertase, C3bBb, is well accepted, whereas the role of properdin as pattern recognition molecule is controversial. The ...
EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With a high ...
MedPage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The trial tested two ...
The complement system consists of a number of small proteins found in the blood, in general synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback